Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Nova Labs Ltd	PURIXAN	mercaptopurine	SUSPENSION;ORAL	205919	NDA	Nova Laboratories, Ltd	62484-0020-2	1 BOTTLE in 1 CARTON (62484-0020-2) / 100 mL in 1 BOTTLE (62484-0020-1)	2014-04-28
Nova Labs Ltd	PURIXAN	mercaptopurine	SUSPENSION;ORAL	205919	NDA AUTHORIZED GENERIC	Nova Laboratories, Ltd	62484-1020-4	1 BOTTLE in 1 CARTON (62484-1020-4) / 100 mL in 1 BOTTLE (62484-1020-3)	2025-09-08
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This report analyzes the global supplier landscape for the pharmaceutical drug PURIXAN (purinethol), focusing on key active pharmaceutical ingredient (API) manufacturers and their patent positions. Understanding these supply chains and patent expirations is critical for strategic R&D, competitive intelligence, and investment decisions.

What is PURIXAN and its Therapeutic Use?

PURIXAN is a brand name for the drug mercaptopurine. Mercaptopurine is an antimetabolite and thiopurine drug used in the treatment of certain types of cancer, primarily acute lymphoblastic leukemia (ALL) in children and other acute leukemias in adults. It functions by interfering with DNA synthesis, thereby inhibiting the growth of cancer cells. The drug is administered orally.

Active Pharmaceutical Ingredient (API) Production Landscape

The production of mercaptopurine API involves complex chemical synthesis processes. The number of significant global API manufacturers for mercaptopurine is limited, reflecting the specialized nature of its production and the regulatory hurdles involved. Key regions with established API manufacturing capabilities include India and China, alongside some production in Europe and North America.

Manufacturer Location	Key Strengths
India	Cost-effective manufacturing, established chemical infrastructure, large volume production.
China	Growing API manufacturing capacity, competitive pricing, expanding regulatory compliance.
Europe/North America	High regulatory standards, advanced synthesis technologies, specialized quality control.

Specific manufacturers often operate under contract for generic drug producers or may have their own abbreviated new drug application (ANDA) filings. Companies specializing in cytotoxic APIs and nucleoside analogs are typically involved in mercaptopurine production.

Patent Status of Mercaptopurine and PURIXAN

The original patent for mercaptopurine has long expired. However, pharmaceutical companies often seek to extend market exclusivity through various strategies, including:

Process Patents: Patents covering novel or improved methods of synthesizing the API. These can impact the ability of generic manufacturers to produce the drug.
Formulation Patents: Patents protecting specific dosage forms, excipients, or delivery mechanisms that enhance the drug's efficacy, stability, or patient compliance.
Method of Use Patents: Patents covering new therapeutic indications for the drug.
Polymorph Patents: Patents claiming specific crystalline forms of the API, which can affect bioavailability or stability.

The primary brand for oral mercaptopurine, PURIXAN, is manufactured by Takeda Pharmaceuticals. Understanding the patent landscape for PURIXAN involves examining both the compound itself and any associated intellectual property that might still be active or recently expired.

Key Patent Expirations and Their Impact

While the core compound patent for mercaptopurine is historical, specific process or formulation patents held by the innovator company (or licensed to them) can dictate the timing of generic market entry. Information on specific patent expiry dates for PURIXAN-specific formulations or processes is often proprietary or requires in-depth patent database analysis.

A general search of the U.S. Patent and Trademark Office (USPTO) and European Patent Office (EPO) databases reveals numerous patents related to mercaptopurine synthesis and formulations, some of which may still be in force or have recently expired. For instance, patents related to improved polymorphic forms or specific tablet formulations designed to enhance stability or palatability can impact generic competition.

The expiry of a key formulation or manufacturing process patent typically opens the door for generic manufacturers to file ANDAs in the U.S. or Marketing Authorisation Applications (MAAs) in Europe. This leads to increased price competition and market share erosion for the originator product.

Major API Suppliers and Their Market Position

Identifying specific API suppliers for mercaptopurine can be challenging due to confidentiality agreements between API manufacturers and finished drug product manufacturers. However, several companies are known to be significant players in the API market for cytotoxic drugs and antimetabolites. These often include:

Global Pharmaceutical Chemical Companies: Large, vertically integrated companies with broad API portfolios.
Specialized API Manufacturers: Companies focusing on niche therapeutic areas or specific chemical synthesis capabilities.
Contract Development and Manufacturing Organizations (CDMOs): Companies that provide development and manufacturing services to other pharmaceutical firms.

Examples of regions and countries known for robust API manufacturing include:

India: Companies like Divi's Laboratories, Aurobindo Pharma, and Dr. Reddy's Laboratories are major API exporters, though their specific involvement with mercaptopurine requires direct confirmation.
China: Numerous chemical manufacturers, such as Zhejiang NHU Company Ltd. and various Sinopharm subsidiaries, are active in the global API supply chain.
Europe: Companies in countries like Germany, Switzerland, and Italy often focus on high-value, complex APIs under stringent regulatory oversight.

The market for mercaptopurine API is characterized by:

Quality and Regulatory Compliance: Suppliers must meet stringent Good Manufacturing Practice (GMP) standards and be approved by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Price Sensitivity: For generic drug production, API cost is a significant factor.
Supply Chain Security: Reliable and consistent supply is paramount for pharmaceutical companies.

Competitive Landscape for Generic Mercaptopurine

The generic market for mercaptopurine is driven by the expiry of relevant patents and the ability of generic manufacturers to secure a reliable and cost-effective API supply. Once generic competition enters the market, prices can drop significantly.

Key factors influencing the competitive landscape include:

ANDA Filings: The number of approved ANDAs for mercaptopurine.
API Supplier Diversification: The availability of multiple qualified API suppliers.
Dosage Form Competition: Whether generics are available in the same tablet strength and form as PURIXAN.

The genericization of a drug like mercaptopurine typically leads to:

Increased Market Access: Wider availability due to lower price points.
Reduced Revenue for Originator: As generic products capture market share.
Focus on Brand Differentiation: For originator products, strategies might include emphasizing specific product attributes or patient support programs.

Regulatory Considerations for API Suppliers

Suppliers of mercaptopurine API must comply with a rigorous regulatory framework. This includes:

FDA Approval: For APIs used in drugs marketed in the U.S., suppliers must have their manufacturing facilities inspected and approved by the FDA. Drug Master Files (DMFs) are often submitted to detail the manufacturing process and quality control.
EMA Approval: Similarly, for the European market, compliance with EMA standards and submission of relevant documentation (e.g., Certificate of Suitability to the monographs of the European Pharmacopoeia - CEP) is necessary.
ICH Guidelines: Adherence to International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use guidelines on quality, safety, and efficacy is standard.
Environmental, Health, and Safety (EHS) Standards: Production of cytotoxic compounds requires strict adherence to EHS protocols due to the hazardous nature of the materials.

Failure to meet these standards can result in import alerts, warning letters, or outright rejection of API batches, severely impacting supply chains.

Future Outlook and Strategic Implications

The market for mercaptopurine API is likely to remain stable, driven by its established role in leukemia treatment. However, the competitive landscape will continue to be shaped by:

Ongoing Patent Expirations: Any remaining formulation or process patents will eventually expire, creating further opportunities for generic manufacturers.
Emerging Markets: Growth in emerging economies may increase demand for both branded and generic mercaptopurine.
Supply Chain Resilience: Recent global events have highlighted the importance of robust and diversified API supply chains. Companies may seek to qualify additional suppliers or explore reshoring options for critical APIs.
Advancements in Synthesis: Continuous innovation in chemical synthesis could lead to more efficient or environmentally friendly production methods, potentially altering the cost structure for API manufacturers.

For R&D and investment professionals, monitoring patent databases for new filings related to mercaptopurine and tracking the regulatory approvals of generic manufacturers are essential. Identifying potential API supply disruptions or advantages can inform strategic sourcing and partnership decisions.

Key Takeaways

PURIXAN (mercaptopurine) is a critical antimetabolite for leukemia treatment, with a long-standing history.
The API manufacturing landscape for mercaptopurine is concentrated, with significant production capacity in India and China, alongside established players in Europe and North America.
While the core compound patent has expired, process, formulation, and polymorph patents can influence the timing and nature of generic competition.
API suppliers must adhere to strict GMP and regulatory standards from bodies like the FDA and EMA.
The generic market entry for mercaptopurine will continue to drive price competition and necessitates robust supply chain management.
Future market dynamics will be influenced by patent expirations, emerging market demand, and the pursuit of supply chain resilience.

Frequently Asked Questions

What is the primary therapeutic indication for PURIXAN? PURIXAN is primarily used to treat acute lymphoblastic leukemia (ALL) and other acute leukemias.
Which countries are major hubs for mercaptopurine API manufacturing? India and China are significant global manufacturing hubs for mercaptopurine API, with established capabilities and competitive pricing.
Are there any active patents that currently prevent generic entry of mercaptopurine? The original compound patent for mercaptopurine has expired. However, specific patents related to novel manufacturing processes, formulations, or polymorphic forms may still be in force and could influence generic competition. A detailed patent search is required for definitive analysis.
What are the key regulatory requirements for mercaptopurine API suppliers? Suppliers must comply with Good Manufacturing Practice (GMP) standards and obtain approvals from regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), often involving the submission of Drug Master Files (DMFs) or Certificates of Suitability (CEPs).
How has the patent landscape evolved for mercaptopurine, and what is the impact on the market? The expiration of the original mercaptopurine patent has paved the way for generic competition. While innovator companies may hold secondary patents on specific aspects like manufacturing processes or formulations, the overall trend is towards increased generic market penetration and price reduction.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-approved-drug-products-therapeutic-equivalence-evaluations

[2] European Medicines Agency. (n.d.). European public assessment reports (EPARs). Retrieved from https://www.ema.europa.eu/en/medicines/human/EPARs

[3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from https://www.ich.org/page/guidelines

[4] U.S. Patent and Trademark Office. (n.d.). Patent Search. Retrieved from https://patft.uspto.gov/

[5] European Patent Office. (n.d.). Espacenet Patent Database. Retrieved from https://www.epo.org/searching-services/find-patent-information.html

Suppliers and packagers for PURIXAN

PURIXAN

PURIXAN: Global Supplier Landscape and Patent Implications